CytoDyn Inc. CYDY
Set alert
As of Nov 2, 3:51 PM ET
- YTD
- -18.93%
- 1 year
- -5.42%
- Open
- 0.2429
- Prev close
- 0.22
- Mkt cap
- 333.58M
- Vol
- 276.15K
- Avg vol
- 1.83M
- EPS
- -0.03
- P/E
- 0.00
More statistics
- Low
- 0.22
- High
- 0.2429
- Earnings
- Jan 21, 2025
5D chart
Signals (94)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2:10 PM | 1 hour ago |
| SMA: Bearish | Nov 2, 2:05 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 2:05 PM | 2 hours ago |
| RSI: Overbought | Nov 2, 1:45 PM | 2 hours ago |
| SMA: Bullish | Nov 2, 1:15 PM | 2 hours ago |
| MACD: Buy Signal | Nov 2, 12:35 PM | 3 hours ago |
| SMA: Bearish | Nov 2, 11:20 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 11:20 AM | 4 hours ago |
| MACD: Sell Signal | Nov 2, 11:20 AM | 4 hours ago |
| MACD: Buy Signal | Nov 2, 11:00 AM | 5 hours ago |
| SMA: Bullish | Nov 2, 10:55 AM | 5 hours ago |
| SMA: Bullish | Nov 2, 10:55 AM | 5 hours ago |
| MACD: Sell Signal | Nov 2, 10:50 AM | 5 hours ago |
| SMA: Bearish | Nov 2, 10:40 AM | 5 hours ago |
| SMA: Bearish | Nov 2, 10:40 AM | 5 hours ago |
| SMA: Bullish | Nov 2, 10:15 AM | 5 hours ago |
| MACD: Buy Signal | Nov 2, 9:55 AM | 6 hours ago |
| SMA: Bullish | Nov 2, 9:45 AM | 6 hours ago |
| SMA: Bearish | Oct 30, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 3:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:50 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 3 days ago |
| RSI: Overbought | Oct 30, 1:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:00 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 11:00 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:50 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 29, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 1:45 PM | 4 days ago |
| RSI: Overbought | Oct 29, 1:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:25 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 5 days ago |
| RSI: Oversold | Oct 28, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:25 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:20 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 6 days ago |
| RSI: Oversold | Oct 27, 3:45 PM | 6 days ago |
| RSI: Oversold | Oct 27, 3:25 PM | 6 days ago |
| RSI: Oversold | Oct 27, 3:00 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 2:40 PM | 6 days ago |
| RSI: Oversold | Oct 27, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 2:15 PM | 6 days ago |
| RSI: Oversold | Oct 27, 2:15 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 6 days ago |
| RSI: Oversold | Oct 27, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 6 days ago |
News
6 days ago defenseworld.net
CytoDyn (OTCMKTS:CYDY) Shares Break Below Two Hundred Day Moving Average – Here’s What Happened
Shares of CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $0.25 and traded as…
1 week ago globenewswire.com
CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
VANCOUVER, Washington, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
1 week ago seekingalpha.com
CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript
CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript
1 week ago marketbeat.com
CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO
CytoDyn OTCMKTS: CYDY provided an update on its Phase II CLOVER study of leronlimab in metastatic colorectal cancer, highlighting early circulating tumor DNA, or ctDNA, data, preliminary clinical…
2 weeks ago globenewswire.com
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"),…
2 weeks ago globenewswire.com
CytoDyn to Host Investor Webcast
VANCOUVER, Wash., Oct. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
3 weeks ago globenewswire.com
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
VANCOUVER, Washington, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
1 month ago marketbeat.com
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer
CytoDyn OTCMKTS: CYDY Chief Financial Officer Robert E. Hoffman outlined the company's clinical-development plans for leronlimab, a CCR5-targeting humanized monoclonal antibody being studied in…
1 month ago defenseworld.net
CytoDyn (OTCMKTS:CYDY) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why
CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) shares crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $0.21 and traded as low as $0.1952.…
1 month ago globenewswire.com
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
VANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
2 months ago globenewswire.com
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
VANCOUVER, Washington, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
3 months ago prnewswire.com
Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock
TACOMA, Wash., July 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP announces proposed class action settlement on behalf of purchasers of CytoDyn Inc. common stock between March 27, 2020…
4 months ago globenewswire.com
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11,…
5 months ago globenewswire.com
CytoDyn to Present at the LD Micro Invitational XVI
CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m.
6 months ago seekingalpha.com
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
6 months ago globenewswire.com
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development
6 months ago globenewswire.com
CytoDyn to Host Investor Webcast
VANCOUVER, Washington, April 23, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
6 months ago globenewswire.com
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a…
6 months ago globenewswire.com
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States
6 months ago globenewswire.com
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
Translational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, modulates immune checkpoint signaling, and is associated…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
Stocks That Hit 52-Week Highs On Thursday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
Stocks That Hit 52-Week Highs On Wednesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday
-
12 years ago benzinga.com
3 Ways To Profit From Merger Activity In The Pharmaceutical Sector
3 Ways To Profit From Merger Activity In The Pharmaceutical Sector